CLOSE

Radiotherapy

highlight

  • Radiation Therapy is available to hit selectively malignant tissue, using "Smart Ray" that allow identifying with precision the target tumor, saving the surronding healthy tissues, preserving the organs and their functions, reducing the treatments duration.
  • IEO Radiotherapy is equipped with the new generation machines able to perform high precision treatment by employing intensity modulation, image guidance, stereotacticapproach, intraoperative irradiation and brachitherapy.

 

The Division includes the following units:Brachitherapy Unit

 

Our Activities

The Division of Radiotherapy is fully committed to three main activities: patient care, research, and teaching. The Division has the latest equipment available for high-precision radiotherapy like Intensity Modulated Radiotherapy (IMRT, including dynamic arc and IMRT using RapidArc technology), Image-Guided Radiotherapy (IGRT), respiratory gating, intra- and extra-cranial stereotactic radiotherapy (SRS, SBRT), 3-D conformal radiotherapy, brachytherapy, and Proton Therapy. Every year more than 3000 patients receive highly selective radiotherapy based on the personalized treatment program defined in the majority of cases in the multidisciplinary tumor board.

High-precision radiotherapy allows for excellent tumor targeting and maximum sparing of normal tissue. In consequence, several clinical protocols with dose escalation and accelerated hypofractionated and ultra-hypofractionated schedules (higher dose per fraction, leading to the reduction of the overall treatment time) have been activated. Indeed, the majority of our patients receive short treatment fully compatible with normal life activities.

About 50 clinical research studies are ongoing at our Division, many of them including national and international collaboration and multidisciplinary cancer care pathways. The main and most innovative active trials in this regard are the CRYSTAL trial (https://clinicaltrials.gov/study/NCT04679454), which enrolls patients with early-stage breast cancer to receive a single-fraction ablative preoperative radiosurgery (stereotactic radiotherapy delivered in single fraction of high dose), and the PRO-SPEED trial (https://www.ieo.it/it/PER-I-PAZIENTI/Sperimentazioni-cliniche/Sperimentazioni-cliniche/IEO-1872/), concerning intermediate and high-risk localized prostate cancer, which aims to treat patients with SBRT in 5 fractions on alternate days using CyberKnife image-guided fiducial markers, and boosting dominant prostatic lesion (DIL).

The Division of Radiotherapy also participates in important multicentric international studies including large ESTRO-EORTC initiatives: the OligoRARE study, a randomized open-label phase 3 clinical trial evaluating the role of stereotactic radiotherapy as an adjunct to standard treatment in oligometastatic patients with rare carcinomas; the OLIGOCARE study, a pragmatic observational study to evaluate RT treatment with radical intent in oligo-metastatic patients; and the RE-CARE study, an observational study to evaluate reirradiation with curative doses.

Other important ongoing trials are the phase II RADIOSA trial (https://clinicaltrials.gov/study/NCT03940235), randomizing patients with prostate cancer to receive radiotherapy alone or radiotherapy plus a short course (6 months) of hormonal therapy, and the observational clinical trial MONDRIAN (https://clinicaltrials.gov/study/NCT05974475) that enrolls patients with lung cancer treated with either hypofractionated radiotherapy or surgery with the goal of understanding which clinical, imaging, and biological factors are associated with response to radiotherapy through the development of predictive models.

In research activities of the Division, the emphasis is placed on breast cancer, urological tumors, and head and neck and other adult solid tumors. The main accent is focused on the combined modality approach, high precision radiotherapy, hypofractionation and ablative radiotherapy, oligometastatic disease, and new prognostic and predictive factors. Last but not least, quality of life and reduction of radiotherapy toxicity are extensively studied.

The Brachytherapy Unit is a full-profile unit equipped with both pulsed- and high-dose-rate systems. The unit is committed to the integrated approach in the field of radiotherapy and multidisciplinary cancer care

The Division of Radiotherapy works in convention with the Milan University (Università degli Studi di Milano) and is chaired by Full Professor of Radiation Oncology Prof. Jereczek and includes numerous university research staff, PhD candidates and residents (residency program of radiation oncology). Educational activities of the Division include in-department teaching for pre- and postgraduate medicine, physics, biomedical omics, biotechnology students, and radiology & radiotherapy bachelor degree students (University of Milan and Politecnico of Milan). Every year our Division hosts about 10 observers from all over the world.

Proton Radiotherapy

Proton Therapy represents the latest frontier in radiotherapy, ensuring a further reduction in the exposure of healthy tissue and consequently a reduction in toxicity. In some cases, an increase in the total dose to the tumor will be possible with a potentially higher probability of oncological success. Since November 2023 a Proton Therapy center has been operational in the department allowing our patients access to this cutting-edge technology. The Radiotherapy Division is equipped with ProteusOne equipment (located in the new 'Proton Centre' building) which will allow Proton Therapy treatments to be performed.

Learn more about Proton Radiotherapy.

The Division includes the following unit: Brachitherapy Unit

  • Our staff
     

    Radiotherapy

    Director

    Barbara Alicja Jereczek

    Staff Radiotherapy

  • offered treatments
    • Cyberknife System - This is a miniature linac dedicated to robot-assisted radiosurgery i.e. delivery of a single high dose of radiation, stereotactically directed to the target. The robotic arm enables the system to deliver radiation from many different directions, verifying instantaneously the target position. This non-invasive, frameless, high precision (submillimetric accuracy) approach allows delivery of the ablative dose to any part of the human body. In IEO, CyberKnife is employed for radiosurgery of primary and metastatic cranial and spine tumors, selected tumors of lung, pancreas, liver, and other abdominopelvic malignancies.

    • TomoTherapy - This is a novel system that combines CT imaging with a radiation treatment delivery system that administers the dose slice-by-slice. With this unique design, the intensity of the radiation beam delivered conforms to the patient’s tumor and helps avoid critical structures as the machine rotates 360 degrees around the patient. Large and irregularly shaped areas may be adequately treated. 

    • Trilogy™ System - This advanced radiotherapy versatile technology enables several irradiation modalities, including RapidArc approach (Volumetric Modulated Arc Therapy). By using real-time diagnostic data, the sculpted radiation beam pinpoints the tumor and protects the surrounding healthy tissue, while minimizing the patient's time on the treatment table. High precision radiation is delivered two to eight times faster than any other system making the experience more comfortable for the patient. In IEO, Trilogy is employed for head and neck cancer tumors (enabling parotid parotid-sparing approach) and for pelvic volumes (gynecological, urological, or intestinal malignancies when pelvic lymph node irradiation is necessary).

    • Truebeam™ System  - This advanced radiotherapy system represents a new possibility for effective treatment of patients with pelvic cancers, abdominal metastases, and inoperable tumors of the liver, pancreas, and lung. It allows the delivery of radiation in targeted, very high doses in seconds and is capable of delivering therapy to both static and moving targets, synchronizing irradiation with the patient's respiratory act, a requirement for treating motion-prone tumors, such as those affecting the lung and abdominal districts. The consequent therapeutic result is an increased likelihood of disease control, with sparing of healthy tissue.

    giveme5

     

  • CLINICAL TRIALS IN EVIDENCE
  • publications

PARTNERSHIP

Università degli Studi di Milano

MAIN CREDITS

Ministero della Salute Joint Commission International bollinirosa

© 2013 Istituto Europeo di Oncologia - via Ripamonti 435 Milano - P.I. 08691440153 - Codice intermediario fatturazione elettronica: A4707H7

IRCCS - ISTITUTO DI RICOVERO E CURA A CARATTERE SCIENTIFICO